Fairscale Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Fairscale Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.12K	Buy	+2	New	+$1.02K	﹤0.01%	437

Other funds holding VRTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Fairscale Capital's VRTX Position: Q3 2026 in Review

Fairscale Capital opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 2 shares worth $1.12K. The stake represents ﹤0.01% of the portfolio and ranks #437 among its holdings.

992 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Fairscale Capital held 2 shares of Vertex Pharmaceuticals worth $1.12K as of Q3 2026.
Vertex Pharmaceuticals was a new Fairscale Capital position in Q3 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Fairscale Capital's portfolio in Q3 2026, its #437 holding.
992 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Fairscale Capital's 13F filing for Q3 2026, filed 4 Nov 2026.